Compounded Semaglutide: What It Is, Whether It's Legal, and What It Costs

You have probably read two very different takes on compounded GLP-1 medications. One side says they are a smart, affordable alternative to overpriced brand-name drugs. The other says they are unregulated, dangerous, and illegal. Neither version is the full story.

The factual answer requires understanding what compounding pharmacies are, what federal law allows them to do, why GLP-1 compounding became widely available when it did, and what the current regulatory picture looks like after two major drugs came off the FDA shortage list. This page covers all of that.

One thing to be clear about upfront: Compounded medications are not FDA-approved products. They have not been reviewed by the FDA for safety, efficacy, or quality. This is not a technicality or fine print. It is a meaningful distinction that should factor into any decision you make. We will say it more than once on this page because it matters.

What compounding pharmacies are and what they do

Pharmaceutical compounding is the practice of preparing a medication specifically for an individual patient, outside the standard manufacturing process used to produce commercially available drugs. Compounding pharmacies have existed for most of the history of modern medicine. Before pharmaceutical manufacturing became industrialized, most medications were compounded by pharmacists.

Today, compounding pharmacies are most commonly used in situations where:

• A patient needs a specific dose that is not available in a commercially manufactured form
• A patient cannot tolerate an ingredient (a dye, a preservative, a filler) in the commercial version
• A medication has been discontinued and no commercial source exists
• A patient needs a different delivery format than the commercial version provides

Federal law regulates compounding pharmacies through the Drug Quality and Security Act of 2013, which created two regulatory categories: 503A pharmacies and 503B outsourcing facilities.

503A vs. 503B: what the distinction means

Understanding the difference between these two categories matters for evaluating the compounding pharmacy your medication comes from.

503A pharmacies are traditional, patient-specific compounding pharmacies. They are licensed by state pharmacy boards. They can only compound medications based on a valid, individual patient prescription from a licensed prescriber. They cannot produce medications in bulk or distribute to healthcare facilities without patient-specific orders. 503A pharmacies are not FDA-registered and are not subject to federal Current Good Manufacturing Practice (CGMP) standards, though state pharmacy boards set their own standards.

503B outsourcing facilities are a category created by the 2013 federal law. They are FDA-registered, subject to CGMP standards, and can compound medications in larger batches without patient-specific prescriptions. They can distribute to healthcare facilities. Because they are FDA-registered and CGMP-compliant, they face a higher and more uniform regulatory bar than 503A pharmacies.

For a deeper comparison, see our dedicated page: 503A vs. 503B compounding pharmacies explained.

Neither 503A nor 503B pharmacies produce FDA-approved medications. FDA registration (for 503B) is not the same as FDA approval of the compounded product. That distinction is critical and frequently misrepresented in GLP-1 marketing.

How FDA drug shortages created the legal basis for GLP-1 compounding

Federal law includes a specific provision that permits compounding pharmacies to prepare copies of drugs that are on the FDA’s official drug shortage list. The statutory basis is 21 U.S.C. 503A(b)(1)(D) for 503A pharmacies and 21 U.S.C. 503B(a)(2)(A) for 503B outsourcing facilities.

The FDA maintains the drug shortage list based on reports from manufacturers and healthcare providers. When a drug is listed, it signals that commercial supply is insufficient to meet patient demand.

Semaglutide was added to the FDA drug shortage list, which made it legal for compounding pharmacies to prepare compounded semaglutide for patients. This is the legal foundation that allowed GLP-1 compounding to scale from small-scale traditional pharmacy use to a significant market segment.

Tirzepatide was also listed on the shortage list during a period of high demand and constrained supply.

The FDA removed semaglutide from the shortage list in early 2025. Tirzepatide’s removal followed. Once a drug comes off the shortage list, the legal basis for compounding that drug under the shortage exemption no longer applies in the same way. The FDA has issued guidance and warning letters indicating that continued compounding of semaglutide and tirzepatide after shortage list removal raises legal questions that are still being worked out through agency guidance, litigation, and enforcement action.

Transformation Health monitors FDA guidance on this closely. Compounded GLP-1 availability may change as the regulatory environment evolves. This is not a hypothetical risk. As of early 2026, the FDA has issued multiple rounds of warning letters to telehealth companies for marketing compounded GLP-1 medications in ways that may not comply with post-shortage legal requirements.

What compounded GLP-1 medications are and are not

What they are:

Compounded semaglutide and tirzepatide are preparations made by licensed US compounding pharmacies using active pharmaceutical ingredients (APIs) sourced from registered API suppliers. They are prepared in controlled settings and, at reputable pharmacies, undergo batch testing to verify potency and purity.

A prescription from a licensed healthcare provider is required. An independent, licensed provider evaluates the patient’s health history and determines whether a compounded GLP-1 medication is clinically appropriate. If clinically appropriate, the prescription is sent to the compounding pharmacy.

What they are not:

Compounded semaglutide and tirzepatide are not FDA-approved drugs. They have not gone through the FDA’s drug approval process, which evaluates a specific manufacturer’s specific formulation for safety, efficacy, and quality. They are not generics. Generic drugs are FDA-approved products that go through an Abbreviated New Drug Application (ANDA) process. Compounded drugs do not go through that process.

Compounded versions should not be described as equivalent to, identical to, or interchangeable with brand-name versions. The active pharmaceutical ingredient may be the same compound, but the formulation, excipients, sterility testing, stability data, and manufacturing controls differ. This is why FDA regulations prohibit language implying equivalence.

Quality indicators: what to look for in a compounding pharmacy

Quality in compounding pharmacy practice is real and verifiable, but it is not uniform. Here is what to look for:

State pharmacy board license. Every compounding pharmacy should hold an active license in the state where it operates. You can verify this through the state pharmacy board website. A license should be current, not expired or under disciplinary action.

PCAB accreditation. The Pharmacy Compounding Accreditation Board (PCAB) is an independent accreditation body that evaluates compounding pharmacies against standards for quality and safety. PCAB accreditation is voluntary, but it is the strongest independent quality signal available for 503A compounders. Not all pharmacies are accredited; those that are have elected to undergo external review.

Certificate of analysis (COA) for each batch. A reputable compounding pharmacy performs testing on each batch of compounded medication to verify that it contains the stated active ingredient at the stated potency, and that it meets sterility and purity standards. This testing is done by an independent third-party laboratory. A COA documents those results. Patients can request to see the COA for their medication lot. If a pharmacy cannot or will not provide one, that is a red flag.

FDA inspection history. For 503B outsourcing facilities, FDA inspection records are publicly available. You can search the FDA database for inspection results, 483 observations (documented deficiencies found during inspections), and warning letters. A clean inspection history, or responsiveness to any identified issues, indicates a pharmacy that takes quality seriously.

Clean regulatory history. Check whether the pharmacy has received FDA warning letters, state board disciplinary actions, or adverse event reports related to its compounded products.

Transformation Health works with US-based, state-licensed compounding pharmacies. We do not partner with pharmacies that have unresolved regulatory issues or that cannot produce batch-level testing documentation.

The post-shortage picture: what 2025-2026 means for compounded GLP-1

The removal of semaglutide and tirzepatide from the FDA shortage list in 2025 changed the legal landscape for GLP-1 compounding in ways that are still being sorted out.

The FDA’s position, as stated in guidance documents and warning letters issued in late 2025 and early 2026, is that compounding pharmacies cannot continue to produce copies of these medications under the shortage exemption once the drugs are no longer on the shortage list. The FDA has indicated it intends to take enforcement action against compounders and telehealth companies that continue marketing these products as if the shortage exemption applies.

This does not mean all compounded GLP-1 medications immediately became unavailable or illegal overnight. The legal picture is more complicated than that. Some pharmacies argue that patient-specific compounding can continue under different provisions (such as the clinical necessity exemption under 503A). Courts and administrative proceedings are still working through some of these questions.

What it does mean: the availability of compounded GLP-1 medications is not guaranteed to continue, and any company that represents otherwise is not being accurate. We are not able to promise ongoing availability. What we can tell you is what we offer today and what our current pharmacy partners are licensed and operating to provide.

For an updated summary of compounding rules post-shortage, see: Compounded GLP-1 after the shortage.

How Transformation Health approaches compounding pharmacy selection

Transformation Health works exclusively with US-based, state-licensed compounding pharmacies. We do not source medications from overseas suppliers or unlicensed facilities.

All prescriptions are evaluated and approved by independent, licensed healthcare providers before any medication is dispensed. Transformation Health is a technology platform that connects patients with care via private networks. The clinical decision about whether a compounded GLP-1 medication is appropriate rests entirely with the independent provider.

What’s in this section

This section covers compounded GLP-1 medications across seven supporting pages:

Compounded tirzepatide: legal status, safety, cost - What compounded tirzepatide is, where it stands legally after the shortage, and how its cost compares to the brand-name version.

Is compounded semaglutide safe - A detailed look at the safety evidence, what FDA has said, and how to evaluate risk for yourself.

503A vs. 503B compounding pharmacies - A clear explanation of the two regulatory categories, what each means for quality standards, and why the distinction matters.

Cost of compounded semaglutide vs. brand - A transparent cost comparison, what drives the price difference, and what is not included in low-cost programs.

How to choose a safe compounding pharmacy - A practical checklist for verifying a pharmacy’s legitimacy before you fill a prescription there.

GLP-1 recalls and safety alerts: FDA data - A running summary of FDA recall actions, safety alerts, and warning letters related to compounded GLP-1 medications.

Compounded GLP-1 after the shortage - What the removal of semaglutide and tirzepatide from the FDA shortage list means for the legality and availability of compounded versions.

Back to the GLP-1 cost and pricing overview.

What to do if you are evaluating this option

If you are considering a compounded GLP-1 program, the starting point is an evaluation by a licensed provider who can review your health history and determine whether this is clinically appropriate for you. That is what the intake process at Transformation Health provides.

The free assessment takes about 10 minutes. An independent, licensed provider reviews your information and recommends a plan, if one is appropriate. You are not charged until after a provider approves a prescription.

Residents of AR, DC, DE, MS, NM, RI, and WV are required by state law to complete a live video consultation before a prescription can be written.